|
JP2938527B2
(ja)
*
|
1990-07-30 |
1999-08-23 |
株式会社リコー |
自動原稿給送装置
|
|
MX2010006466A
(es)
*
|
2007-12-14 |
2010-09-28 |
Bristol Myers Squibb Co |
Moleculas de union al receptor ox40 de humano.
|
|
WO2010096418A2
(en)
*
|
2009-02-17 |
2010-08-26 |
Ucb Pharma S.A. |
Antibody molecules having specificity for human ox40
|
|
WO2012015696A1
(en)
*
|
2010-07-26 |
2012-02-02 |
Baylor Research Institute |
Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
|
|
EA029793B1
(ru)
|
2010-08-23 |
2018-05-31 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела к ох40 и способы их применения
|
|
KR101527300B1
(ko)
|
2010-09-09 |
2015-06-09 |
화이자 인코포레이티드 |
4-1ｂｂ 결합 분자
|
|
AU2012282116B2
(en)
*
|
2011-07-11 |
2016-07-07 |
Ichnos Sciences SA |
Antibodies that bind to OX40 and their uses
|
|
KR101685262B1
(ko)
*
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ｏｘ４０ 항체 및 이의 사용 방법
|
|
GB201116092D0
(en)
*
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
KR101935088B1
(ko)
|
2012-08-24 |
2019-01-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
|
US20150322119A1
(en)
|
2012-12-03 |
2015-11-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
CA2907436A1
(en)
|
2013-03-18 |
2014-09-25 |
Biocerox Products B.V. |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
EP3995507B1
(en)
|
2013-08-08 |
2023-10-04 |
Cytune Pharma |
Il-15 and il-15ralpha sushi domain based on modulokines
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
KR102127408B1
(ko)
*
|
2014-01-29 |
2020-06-29 |
삼성전자주식회사 |
항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
|
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
|
EP3126394B1
(en)
*
|
2014-03-31 |
2019-10-30 |
F.Hoffmann-La Roche Ag |
Anti-ox40 antibodies and methods of use
|
|
CA2954056C
(en)
|
2014-07-11 |
2020-04-28 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
TW201619200A
(zh)
*
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
WO2016073282A1
(en)
*
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
CA2967368A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
PL3242890T3
(pl)
*
|
2015-01-08 |
2020-04-30 |
BioNTech SE |
Czynniki agonistyczne wiążące się z receptorem TNF
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
NZ733854A
(en)
|
2015-02-26 |
2022-07-01 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
KR20250005465A
(ko)
|
2015-03-03 |
2025-01-09 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
MA42043A
(fr)
*
|
2015-05-07 |
2018-03-14 |
Agenus Inc |
Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
|
|
EP3298045A1
(en)
*
|
2015-05-21 |
2018-03-28 |
Alligator Bioscience AB |
Novel polypeptides
|
|
FI3303396T3
(fi)
*
|
2015-05-29 |
2023-02-22 |
|
Vasta-aineita ox40:ää vastaan ja niiden käyttöjä
|
|
GB201509338D0
(en)
*
|
2015-05-29 |
2015-07-15 |
Bergenbio As |
Combination therapy
|
|
JP6876629B2
(ja)
|
2015-06-16 |
2021-05-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｐｄ−ｌ１アンタゴニスト併用療法
|
|
EP3112381A1
(en)
*
|
2015-07-01 |
2017-01-04 |
FONDAZIONE IRCCS Istituto Nazionale dei Tumori |
Bispecific antibodies for use in cancer immunotherapy
|
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
US20180263985A1
(en)
|
2015-09-15 |
2018-09-20 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
|
CN115594765A
(zh)
|
2015-10-02 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
对共刺激性tnf受体特异性的双特异性抗体
|
|
EP3363816A4
(en)
*
|
2015-10-15 |
2019-10-09 |
Dingfu Biotarget Co., Ltd. |
ANTI-OX40 ANTIBODIES AND USES THEREOF
|
|
LT3370768T
(lt)
|
2015-11-03 |
2022-05-25 |
Janssen Biotech, Inc. |
Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
|
|
ES2913208T3
(es)
|
2015-12-01 |
2022-06-01 |
Glaxosmithkline Ip Dev Ltd |
Tratamientos de combinación y usos y métodos de los mismos
|
|
TWI717432B
(zh)
*
|
2015-12-02 |
2021-02-01 |
美商艾吉納斯公司 |
抗體和使用彼之方法
|
|
WO2017093933A1
(en)
|
2015-12-03 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
KR20210013777A
(ko)
*
|
2016-01-25 |
2021-02-05 |
화이자 인코포레이티드 |
암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
MX2018012333A
(es)
|
2016-04-07 |
2019-03-07 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas utiles como moduladores de proteinas.
|
|
BR112018070602A2
(pt)
|
2016-04-07 |
2019-02-05 |
Glaxosmithkline Ip Dev Ltd |
composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
AU2017260854B2
(en)
|
2016-05-05 |
2020-01-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of Zeste Homolog 2 inhibitors
|
|
MX2018016344A
(es)
|
2016-06-20 |
2019-05-30 |
F Star Beta Ltd |
Miembros de union lag-3.
|
|
WO2018005519A2
(en)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Cancer treatment combinations
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
CA3203613A1
(en)
*
|
2016-07-19 |
2018-01-25 |
Ibentrus, Inc. |
Bispecific proteins and methods for preparing same
|
|
KR20190028540A
(ko)
|
2016-07-20 |
2019-03-18 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Perk 억제제로서의 이소퀴놀린 유도체
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
AU2017308590A1
(en)
|
2016-08-12 |
2019-02-14 |
Janssen Biotech, Inc. |
Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
|
|
CA3077518C
(en)
*
|
2016-09-07 |
2021-10-19 |
Frederic Fellouse |
Synthetic antibodies against vegf and their uses
|
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avelumab for the treatment of cancer
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
EP3548068A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
|
KR20190090822A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
|
HUE050399T2
(hu)
|
2016-12-15 |
2020-12-28 |
Abbvie Biotherapeutics Inc |
Anti-OX40 antitestek és alkalmazásuk
|
|
AU2017384528A1
(en)
|
2016-12-19 |
2019-07-04 |
Ichnos Sciences SA |
Novel TNFR agonists and uses thereof
|
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族（ｔｎｆｒｓｆ）促效劑使腫瘤浸潤淋巴球（ｔｉｌ）擴增及ｔｉｌ與ｔｎｆｒｓｆ促效劑的治療組合
|
|
EP3585782A1
(en)
|
2017-02-27 |
2020-01-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
CN108623686A
(zh)
*
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
CN110831971A
(zh)
|
2017-06-09 |
2020-02-21 |
葛兰素史克知识产权开发有限公司 |
用icos激动剂和ox40激动剂治疗癌症的组合疗法
|
|
US20200181275A1
(en)
|
2017-06-09 |
2020-06-11 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy with icos agonist and ox40 agonist to treat cancer
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
CN111511762A
(zh)
|
2017-08-21 |
2020-08-07 |
天演药业公司 |
抗cd137分子及其用途
|
|
EP3672634A1
(en)
*
|
2017-08-24 |
2020-07-01 |
Invenra, Inc. |
Multivalent receptor-clustering agonist antibody constructs
|
|
NZ761401A
(en)
*
|
2017-08-31 |
2022-11-25 |
Io Therapeutics Inc |
Rar selective agonists in combination with immune modulators for cancer immunotherapy
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
|
EP3692034A1
(en)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
KR20200100060A
(ko)
|
2017-11-17 |
2020-08-25 |
이오반스 바이오테라퓨틱스, 인크. |
미세 바늘 흡인물 및 소형 생검물로부터의 til 확장
|
|
CN112292397B
(zh)
*
|
2017-11-24 |
2023-01-31 |
祐和医药科技(北京)有限公司 |
抗ox40抗体及其用途
|
|
US11142579B2
(en)
|
2017-12-06 |
2021-10-12 |
Sorrento Therapeutics, Inc. |
Variant antibodies that bind OX40
|
|
BR112020013133A2
(pt)
*
|
2017-12-29 |
2020-12-08 |
Ap Biosciences, Inc. |
Proteínas monospecíficas e bispecíficas com regulação do ponto de verificação imune para terapia do câncer
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
CN111836887A
(zh)
|
2018-01-08 |
2020-10-27 |
艾欧凡斯生物治疗公司 |
产生富含肿瘤抗原特异性t细胞的til产品的方法
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
EP3752600A1
(en)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
TWI831776B
(zh)
|
2018-04-27 |
2024-02-11 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途
|
|
KR20210039986A
(ko)
*
|
2018-05-11 |
2021-04-12 |
우시 바이올로직스 (상하이) 컴퍼니 리미티드 |
Ox40에 대한 완전한 인간 항체, 이를 준비하는 방법 및 이의 용도
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
|
CA3100828A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
WO2020011966A1
(en)
|
2018-07-12 |
2020-01-16 |
F-Star Beta Limited |
Antibody molecules that bind cd137 and ox40
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
US20210277135A1
(en)
|
2018-07-13 |
2021-09-09 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
CA3112599A1
(en)
|
2018-09-20 |
2020-03-26 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
|
JP2022512915A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
改良された腫瘍反応性ｔ細胞の選択
|
|
AU2019377422A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
|
SG11202104615VA
(en)
|
2018-11-05 |
2021-06-29 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
|
CA3118542A1
(en)
*
|
2018-11-09 |
2020-05-14 |
Beth Israel Deaconess Medical Center |
Cdcp1-targeted therapies
|
|
US20220193131A1
(en)
|
2018-12-19 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
CN113924317A
(zh)
|
2019-02-01 |
2022-01-11 |
葛兰素史克知识产权开发有限公司 |
贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症
|
|
CN114269370A
(zh)
|
2019-03-29 |
2022-04-01 |
迈斯特治疗公司 |
离体产生t细胞治疗剂的方法以及相关的组合物和方法
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20230053328A9
(en)
|
2019-05-24 |
2023-02-16 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
EP3976090A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN110172090B
(zh)
*
|
2019-06-03 |
2020-04-03 |
中山标佳生物科技有限公司 |
Cd134单克隆抗体及其制备方法和癌症治疗中的应用
|
|
CN114222760A
(zh)
|
2019-06-26 |
2022-03-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
Il1rap结合蛋白
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
CA3155173A1
(en)
|
2019-09-27 |
2021-04-01 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
US20220389381A1
(en)
|
2019-10-25 |
2022-12-08 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US20230220341A1
(en)
|
2019-12-11 |
2023-07-13 |
lovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
AU2020410410A1
(en)
|
2019-12-17 |
2022-06-09 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
|
US20230062932A1
(en)
|
2019-12-18 |
2023-03-02 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021124096A1
(en)
|
2019-12-18 |
2021-06-24 |
Pfizer Inc. |
Once daily cancer treatment regimen with a prmt5 inhibitor
|
|
WO2021152495A1
(en)
|
2020-01-28 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2021174208A1
(en)
|
2020-02-27 |
2021-09-02 |
Myst Therapeutics, Llc |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
EP4118105A2
(en)
|
2020-03-09 |
2023-01-18 |
Pfizer Inc. |
Cd80-fc fusion protein and uses thereof
|
|
WO2021190431A1
(zh)
|
2020-03-23 |
2021-09-30 |
百奥泰生物制药股份有限公司 |
一种免疫细胞激活剂的开发及应用
|
|
US20230035733A1
(en)
*
|
2020-03-26 |
2023-02-02 |
Dusa Pharmaceuticals, Inc. |
Management of dermal neurofibromatosis lesions
|
|
CA3175413A1
(en)
|
2020-04-17 |
2021-10-21 |
Yizhen Yang |
Anti-ox40 antibody and uses thereof
|
|
WO2021226061A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
WO2021226085A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
WO2021229507A2
(en)
|
2020-05-13 |
2021-11-18 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
AU2021308586A1
(en)
|
2020-07-17 |
2023-03-02 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
|
AU2021339096A1
(en)
|
2020-09-14 |
2023-04-06 |
Pfizer Inc. |
Methods, therapies and uses for treating cancer
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
CN114515335A
(zh)
|
2020-11-19 |
2022-05-20 |
百奥泰生物制药股份有限公司 |
抗ox40抗体在治疗肿瘤或癌症中的应用
|
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
EP4262811A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022153161A1
(en)
|
2021-01-14 |
2022-07-21 |
Pfizer Inc. |
Treatment of cancer using a prmt5 inhibitor
|
|
EP4288140A1
(en)
|
2021-02-05 |
2023-12-13 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
KR20230154230A
(ko)
|
2021-03-02 |
2023-11-07 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Dnmt1 억제제로서의 치환된 피리딘
|
|
WO2022198055A1
(en)
*
|
2021-03-19 |
2022-09-22 |
KSQ Therapeutics, Inc. |
Uses of antagonist, non-depleting ox40 antibodies
|
|
EP4314060A1
(en)
|
2021-03-31 |
2024-02-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
|
|
US20250000903A1
(en)
|
2021-09-24 |
2025-01-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
EP4423755A2
(en)
|
2021-10-27 |
2024-09-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
US20250032618A1
(en)
|
2021-11-10 |
2025-01-30 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
CN118574849A
(zh)
|
2021-12-17 |
2024-08-30 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体和使用方法
|
|
JP2024547020A
(ja)
|
2021-12-17 |
2024-12-26 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｏｘ４０抗体、多重特異性抗体及びその使用方法
|
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
|
KR20250010064A
(ko)
|
2022-06-17 |
2025-01-20 |
화이자 인코포레이티드 |
Il-12 변이체, 항-pd1 항체, 융합 단백질, 및 그의 용도
|
|
WO2024003773A1
(en)
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
AU2023302139A1
(en)
|
2022-07-05 |
2024-12-19 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024074977A1
(en)
|
2022-10-04 |
2024-04-11 |
Pfizer Inc. |
Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
|
|
WO2024084364A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Compounds for the treatment of cancer
|
|
WO2024105563A1
(en)
|
2022-11-16 |
2024-05-23 |
Pfizer Inc. |
Substituted bicyclic pyridone derivatives
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2024209339A1
(en)
|
2023-04-05 |
2024-10-10 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
WO2024213979A1
(en)
|
2023-04-10 |
2024-10-17 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
WO2024218686A1
(en)
|
2023-04-20 |
2024-10-24 |
Pfizer Inc. |
Pyrido[4,3-d]pyrimidine compounds
|
|
US20240400703A1
(en)
|
2023-05-12 |
2024-12-05 |
Genmab A/S |
Antibodies capable of binding to ox40, variants thereof and uses thereof
|